favipiravir - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.76 [0.26, 2.24]< 10%4 studies (4/-)68.8 %some concernnot evaluable moderatecrucial-
clinical improvement 1.58 [1.13, 2.21]> 119%3 studies (3/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.10 [0.58, 2.11]> 131%2 studies (2/-)61.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.32 [0.86, 2.03]> 170%2 studies (2/-)89.4 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.50 [1.02, 2.21]> 10%1 study (1/-)97.9 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.67 [1.26, 2.23]> 10%2 studies (2/-)100.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.41 [0.97, 2.03]> 10%1 study (1/-)96.6 %some concernnot evaluable moderateimportant-
PCR-negative conversion 1.83 [1.12, 2.99]> 167%5 studies (5/-)99.2 %some concernserious moderateimportant-
PCR-negative conversion (14-day) 1.30 [0.50, 3.36]> 148%2 studies (2/-)70.5 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.44 [0.78, 2.65]> 161%3 studies (3/-)87.5 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only) 1.32 [1.03, 1.69]> 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
ventilation 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
ICU admission 1.03 [0.35, 3.03]< 10%1 study (1/-)48.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 2.71 [0.41, 18.02]< 10%3 studies (3/-)15.3 %some concernnot evaluable moderateimportant-
adverse events 2.16 [0.82, 5.68]< 180%3 studies (3/-)5.9 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.